Participated · Series A · May 2023

DeepKinase develops industrialized, mass‑spectrometry‑based functional proteomics platforms (including DoTK/DoDT) and product lines such as the QSure 千序 pY‑targeted quantitative platform and the 深迹 reagent kit series. In 2021 the company obtained regulatory approval for six reagent‑kit products (深迹 series), the first clinical proteomics reagent kits approved in China, and its affiliated laboratory received an operating license in February. The firm has built sample‑processing automation, proprietary tumor signaling and immune‑activity databases, PCT patent registrations, and AI‑driven protein analysis tools (including a protein language model proGPT) to enable biomarker and target discovery. Commercially it reports partnerships with more than 30 pharma customers and is a strategic partner of Thermo Fisher and an innovation partner of AstraZeneca. Future plans described by the company include strengthening the technical platform, increasing automation and throughput, optimizing AI‑integrated analysis algorithms, further productization and commercialization, and extending applications across drug R&D, companion diagnostics, early screening, recurrence monitoring and resistance guidance.

Led · Equity · Nov 2017

Saina Biotech, founded by a team including Peking University academician Xie Xiaoliang, Professor Huang Yanyi and Dr. Chen Zitian, is a high-tech company integrating gene-technology R&D, translation, production and sales. The company holds more than a hundred Chinese and PCT patents, with core patents authorized in the United States, and centers its technology on two proprietary sequencing innovations: Fluorogenic signal generation and error-correcting coding (ECC). It operates complete manufacturing and R&D capabilities including chemical and enzyme raw-material bases, a GMP reagent production workshop, an instrument factory, and optical, fluidics and algorithm teams. Based on this platform Saina launched the S100 sequencing system, a high-throughput, dual-mode, fast and accurate platform designed for flexible deployment and to meet domestic clinical needs for small samples, speed and low cost. In June 2022 the S100 instrument and companion reagent kits received EU CE-IVDR certification, clearing the way for sales in the European market. The company says it will continue next-generation sequencing R&D, accelerate S100 commercialization and build a China-led sequencing ecosystem to support national bioinformation security. SainaBio develops and industrializes high-throughput gene sequencing platforms, proprietary chips, and reagents aimed at clinical disease detection, diagnosis, and screening. Its core sequencing technologies—Fluorogenic emission and error-correcting ECC coding—were developed by teams led by prominent scientists including Prof. Xie Xiaoliang and Prof. Huang Yanyi. The company reports a multidisciplinary team of nearly 100 technical staff, with more than one-third of R&D personnel holding doctoral or master’s degrees and an instrument engineering team drawn from top domestic IVD firms. SainaBio has completed研发 and validation of its core technologies and produced a first-generation prototype that the company says matches or exceeds comparable international machines on cost, accuracy, and speed. The firm received a Beijing Municipal Science & Technology Commission project approval in September 2017. Proceeds from the recent financing will be used to finalize clinical registration, optimize and industrialize prototypes, scale instrument and chip production, and support product market entry.